Expediting FDA approvals for biosimilars

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Expediting FDA approvals for biosimilars

Biosimilars/Research | Posted 19/10/2018 0 Post your comment

A number of recommendations for the US Food and Drug Administration (FDA) to simplify biosimilar licensing laws, and thus make biosimilars more accessible, are offered in a recent review [1]. Recommendations include allowing smaller batch sizes for testing, encouraging substitution for naïve patients, and removing the requirement for bridging studies.

Acceptance of biosimilars in the US has been slow, due to high costs (nearly US$250 million) and long development times (around eight years on average). Entrance to the US market has been further hampered by public misunderstanding of the safety of biosimilars, as well as complex licensing laws introduced by FDA.

The Biologics Price Competition and Innovation (BPCI) Act, a part of the Affordable Healthcare Act, was introduced in 2009 to allow the introduction of biosimilars to the US market. However, several of the statutory requirements within the act are left to the discretion of FDA and lead to restrictions for biosimilars manufacturers.

To encourage the faster development and adoption of biosimilar products in the US, the author makes the following major recommendations to FDA:

Waiver bridging studies (currently required where there is a non-US product as a reference product)
Encourage substitution for naïve patients
Allow in vivo immunogenicity study waivers
Make pharmacokinetic profiling clinically relevant
Modify tier testing criteria for analytical similarity
Clarify analytical testing validation
Encourage development of novel testing methods
Accept smaller batch sizes
Minimize clinical studies

The author also suggests terms such as ‘clinically meaningful difference’ and ‘residual uncertainty’ should be better accounted for in the FDA guidance. These recommendations are also the subject of a recent citizen petition filed to FDA.

FDA itself has acknowledged the need for changes to its guidance, demonstrated by Commissioner Scott Gottlieb’s recent expression of willingness to reinterpret the FDA guidelines for the increased approval of biosimilars.

A more detailed discussion of the recommendations is presented in the following paper [1].

Conflict of interest
The authors of the research paper [1] declared no conflict of interest.

Editor’s comment
Readers interested to learn more about FDA legislation on biosimilars are invited to visit www.gabi-journal.net to view the following manuscripts published in GaBI Journal:

Potential changes to the FDA approach to biosimilars have a global impact

Physician associations comment on FDA’s interchangeability guidance

US FDA proposals for naming of biologicals and labelling of biosimilars

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here.

FDA withdraws biosimilar statistical guidance

Analytical similarity for biosimilars

Reference
1. Niazi SK. Rationalizing FDA guidance on biosimilars—expediting approvals and acceptance. Generics and Biosimilars Initiative Journal (GaBI Journal). 2018;7(2):84-91. doi:10.5639/gabij.2018.0702.008

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.